Humacyte, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023; filed November 9, 2023. Humacyte is a clinical-stage regenerative-medicine company developing bioengineered human acellular vessels (HAVs). It has not generated product revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $31,000 | $0 | $1.6 million |
| Research and development expense | $18.6 million | $17.3 million | $56.4 million | $48.3 million |
| General and administrative expense | $6.1 million | $6.2 million | $17.5 million | $17.1 million |
| Operating loss | $24.6 million | $23.5 million | $73.9 million | $63.8 million |
| Net loss | $26.0 million | $25.3 million | $85.7 million | $8.2 million |
| Basic and diluted loss per share | $0.25 | $0.25 | $0.83 | $0.08 |
The company had no product sales; 2022 revenue was grant-related. Gross margin is not applicable to the reported results. Nine-month operating cash use was $54.3 million, versus $52.2 million in 2022. Investing cash use was $23,000; financing provided $4.8 million, including revenue-interest financing and repayment of the SVB loan. Cash, cash equivalents and restricted cash totaled $100.3 million at September 30, 2023, down from $149.8 million at year-end 2022. Working capital was $87.7 million, versus $134.6 million at year-end.
Total assets were $149.4 million and total liabilities $112.4 million. The balance sheet included a $37.3 million revenue-interest liability and $19.4 million in finance lease obligations; no SVB loan remained outstanding. Stockholders’ equity was $37.0 million. The company reported an accumulated deficit of $512.2 million.
Changes and unusual items
- Nine-month R&D expense rose 17% year over year, mainly from higher personnel and external clinical-development costs; management attributed spending to vascular-trauma trial completion and planned BLA preparation, and expanded hemodialysis-access development.
- Nine-month net loss widened sharply from 2022, principally because the 2022 period included a $58.6 million noncash gain from remeasuring the contingent earnout liability. In 2023, its remeasurement produced an $11.7 million noncash loss.
- 2023 other items included a $3.1 million employee-retention credit and a $2.4 million loss on extinguishment of the SVB loan. The credit was recognized after IRS notices confirmed the receivable.
- In May 2023, Humacyte received an initial $40 million gross payment under an agreement to sell revenue interests, using the proceeds to repay its SVB facility. Up to approximately $110 million in further funding is conditional on specified regulatory and sales milestones. The agreement provides for royalties on future global net sales and includes put/call and repayment provisions.
Outlook, commentary and risks
Management expects substantial operating losses and negative operating cash flows for the foreseeable future, with expenses expected to increase as development, potential commercialization preparation and manufacturing scale-up advance. It believes cash on hand will fund operations, clinical trials and capital expenditures for at least 12 months from the report date, but says additional capital will be needed for longer-term plans and may not be available on acceptable terms.
In September 2023, the company announced positive top-line results from its V005 Phase 2/3 vascular-trauma trial and planned to file a BLA for extremity vascular trauma in Q4 2023. Enrollment in the V007 Phase 3 hemodialysis-access trial was completed in March 2023; a BLA supplement is contemplated subject to trial results. These are management plans, not assurances of filing or approval. Key risks include clinical and regulatory outcomes, manufacturing capacity, commercialization and reimbursement, reliance on third parties and strategic partners, and the need for additional capital. The company disclosed $17.4 million of non-cancellable purchase commitments, primarily for R&D supplies and services, and no legal proceedings management believed would have a material adverse effect.
Most important facts for investors to verify
- Progress and timing of the planned vascular-trauma BLA filing, FDA review and V005 results.
- V007 clinical results and the timing and requirements for any hemodialysis-access BLA supplement.
- Cash burn and runway, and whether conditional revenue-interest funding milestones can be achieved.
- Revenue-interest agreement economics, including future royalty burden, repayment terms and put/call triggers.
- Manufacturing readiness, trial costs and potential additional financing or shareholder dilution.